Indication

For the treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.

Medicine details

Medicine name:
ocrelizumab (Ocrevus)
SMC ID:
SMC2223
Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Publication due date:
13 January 2020
SMC meeting date:
03 December 2019
Patient group submission deadline:
30 September 2019